Merck forecasts sharp drop in COVID antiviral pill sales in 2023
The company estimated sales of molnupiravir, which is sold under the brand Lagevrio, to fall to about $1 billion this year from $5.68 billion in 2022
February 2, 2023
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.